miR-146a rs2910164 C>G Polymorphism and Wilms tumor susceptibility in Eastern Chinese children

Background and objectives

Wilms tumor is the most common renal malignancy in children. miR-146a, a highly conserved small noncoding RNA, plays a critical role in various human diseases. Increasing studies have suggested that rs2910164 C>G polymorphism in miR-146a is associated with susceptibility to cancers. However, miR-146a rs2910164 C>G polymorphism influence on Wilms tumor remains unknown. The aim of this study was to evaluate the relationship between miR-146a rs2910164 C>G polymorphism and Wilms tumor susceptibility in Chinese children.

Methods

In the six-center case-control study, we enrolled 1,352 subjects from East China (416 cases and 936 healthy controls). The TaqMan method was adopted to genotype the miR-146a rs2910164 C>G polymorphism. Logistic regression models were utilized to assess the correlation between this polymorphism and the risk of Wilms tumor.

Results

No significant association was observed between miR-146a rs2910164 C>G polymorphism and the susceptibility to Wilms tumor. Further stratification analysis also did not detect a significant relationship.

Conclusions

The present study showed no association of miR-146a rs2910164 C>G polymorphism with the risk of Wilms tumor in the Eastern Chinese population. Subsequent studies with a larger sample size will be required to validate these results.

Full text

The study was recently published in the Cancer Screening and Prevention.

Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.

Follow us on X: @xiahepublishing

Follow us on LinkedIn:  Xia & He Publishing Inc.